Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

31 results
Display

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy

Reddy AV, Hill CS, Sehgal S, Zheng L, He J, Laheru DA, Jesus-Acosta AD, Herman JM, Meyer J, Narang AK

Purpose: To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic cancer treated with anti-PD-1 (programmed cell death protein-1) antibody...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy

Chen Y, Huang H, Liu Y, Wang Z, Wang L, Wang Q, Zhang Y, Wang H

Purpose The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma

An J, Kang HJ, Yu E, Lee HC, Shim JH

Background/Aim: Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors

Hwang S, Kim H, Chung S, Min M, Suh DC

Objective: PD-1 inhibitors have demonstrated improved health outcomes in cancer patients. PD-1 inhibitors are well-tolerated and associated with immune-related adverse events. The objectives of this study are to analyze use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advances in immune checkpoint inhibitors for hepatocellular carcinoma

Han JW, Park SH

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management

Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY

Immune checkpoint inhibitor (ICI) associated cardiovascular adverse events (CVAE) have become more frequent with the growing use of cancer immunotherapy. CVAEs include a wide spectrum of diseases such as myocarditis,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center

Ji YS, Park SH

Purpose The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma

Lee MY, Park CJ, Cho YU, You E, Jang S, Seo EJ, Lee JH, Yoon DH, Suh C

Background: Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy

Zheng B, Shin JH, Li H, Chen Y, Guo Y, Wang M

Objective: To evaluate the radiological tumor response patterns and compare the response assessments based on immunebased therapeutics Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST 1.1 in metastatic clear-cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC

Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

Lim SM, Kim SW, Cho BC, Kang JH, Ahn MJ, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, Kim JH, Lee SS, Na II, Yoo SS, Lee KH

Purpose The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors

Kang DH, Park CK, Chung C, Oh IJ, Kim YC, Park D, Kim J, Kwon GC, Kwon I, Sun P, Shin EC, Lee JE

Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
From Theranostics to Immunotheranostics: the Concept

Schaefer N, Prior JO, Schottelius M

Immunotheranostics will be an important development in the future of nuclear medicine and medical oncology. It describes the synergy of theranostic procedures in nuclear medicine and immune oncology (IO) treatment. In...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy

Kim KH, Kim CG, Shin EC

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation

Im SJ, Ha SJ

Acute viral infection or vaccination generates highly functional memory CD8 T cells following the Ag resolution. In contrast, persistent antigenic stimulation in chronic viral infection and cancer leads to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer

Islam Tultul MS, Koh YS

Programmed cell death protein 1 (PD-1) is an immuno-inhibitory cell surface receptor protein of the myeloid, and lymphoid cell. PD-L1 is the ligand of PD-1, which is abundant in different...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review

Park E, Koo T, Jo M, Yoo J, Park J

  • KMID: 2465922
  • Korean J Dermatol.
  • 2019 Nov;57(9):551-555.
Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cancer Immunotherapy Related Endocrine Adverse Effects

Kim H, Cho SW, Park YJ

Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience

Indini A, Di Guardo , Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M

OBJECTIVE: immunotherapy with immune checkpoint inhibitors has become one of the standard therapeutic modalities for patients with advanced melanoma. Melanoma of the female lower genital tract is a rare and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy

Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ

BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy using antibodies such as nivolumab or pembrolizumab has shown promise for treating various types of cancer. In this study, we reviewed the frequency and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr